To investigate the pharmaceutical effects of HDAC inhibitors on fibrosis, Korfei et al. compared the anti-fibrotic effects between pan-HDAC inhibitor, panobinostat, and pirfenidone using in vitro assays with fibroblasts from IPF patients [16]. This evidence concerns the gene HDAC9 and idiopathic pulmonary fibrosis.